Tag: clinical trials

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

| February 1, 2017 | 0 Comments

by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, PhD; Suzanne Hendrix, PhD; Enchi Liu, PhD; David A. Loewenstein, PhD; Glenn Morrison, MSc, PhD; Leslie Shinobu, PhD; Keith Wesnes, BSc, PhD, FSS, CPsychol, FBPsS; and Philip D. Harvey, PhD Dr. Posner is with Pfizer Inc., New York, New York; Drs. Curiel, Loewenstein, and Harvey […]

Continue Reading

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

| February 1, 2017 | 0 Comments

by Philip D. Harvey, PhD; Stephanie Cosentino, PhD; Rosie Curiel, PhD; Terry E. Goldberg, PhD; Jeffrey Kaye, MD; David Loewenstein, PhD; Daniel Marson, PhD, JD; David Salmon, PhD; Keith Wesnes, PhD; and Holly Posner, MD Drs. Harvey, Curiel, and Loewenstein are with the University of Miami Leonard Miller School of Medicine, Department of Psychiatry and Behavioral Sciences, Miami, Florida; […]

Continue Reading

The Neuroscience Report—Volume 38 (March 22, 2016): Building Better Clinical Trials

The Neuroscience Report—Volume 38 (March 22, 2016): Building Better Clinical Trials

| March 22, 2016 | 0 Comments

The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. This week’s […]

Continue Reading

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders

| February 1, 2016 | 2 Comments

by the CNS SUMMIT DATA QUALITY MONITORING WORKGROUP CORE MEMBERS—David Daniel, MD; Amir Kalali, MD; Mark West; David Walling, PhD; Dana Hilt, MD; Nina Engelhardt, PhD; Larry Alphs, MD, PhD; Antony Loebel, MD; Kim Vanover, PhD; Sarah Atkinson, MD; Mark Opler, PhD, MPH; Gary Sachs, MD; Kari Nations, PhD; and Chris Brady, PsyD Dr. Daniel […]

Continue Reading

The Neuroscience Report—Volume 24 (October 12, 2015): Treatment Paradigm Shifts in CNS

The Neuroscience Report—Volume 24 (October 12, 2015): Treatment Paradigm Shifts in CNS

| October 12, 2015 | 0 Comments

The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. This Week’s Topic: Treatment […]

Continue Reading

Editor’s Message and January-February 2015 Issue Highlights

Editor’s Message and January-February 2015 Issue Highlights

| February 25, 2015 | 0 Comments

Dear Colleagues: Welcome to the January-February 2015 issue of Innovations in Clinical Neuroscience and to the beginning of our 12th year of publication. Over the years, we have sought to not only provide you with information on the latest, evidence-based treatment techniques for your patients, but also with information on how these new treatments are […]

Continue Reading

How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?

How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?

| June 1, 2013 | 0 Comments

by Joanne B. Severe, MS, and Annette Stemhagen, DrPH, FISPE Ms. Severe is a research consultant in Rockville, Maryland, and Dr. Stemhagen is with United Biosource Corp. in Bethesda, Maryland. Innov Clin Neurosci. 2013;10(5–6 Suppl A):29S–31S

Continue Reading